BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17671653)

  • 21. [Development and application of gene therapy technologies].
    Ozawa K
    Uirusu; 2004 Jun; 54(1):49-57. PubMed ID: 15449904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hot spots of retroviral integration in human CD34+ hematopoietic cells.
    Cattoglio C; Facchini G; Sartori D; Antonelli A; Miccio A; Cassani B; Schmidt M; von Kalle C; Howe S; Thrasher AJ; Aiuti A; Ferrari G; Recchia A; Mavilio F
    Blood; 2007 Sep; 110(6):1770-8. PubMed ID: 17507662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene therapy for severe combined immunodeficiencies.
    Gaspar HB; Thrasher AJ
    Expert Opin Biol Ther; 2005 Sep; 5(9):1175-82. PubMed ID: 16120048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial.
    Schmidt M; Hacein-Bey-Abina S; Wissler M; Carlier F; Lim A; Prinz C; Glimm H; Andre-Schmutz I; Hue C; Garrigue A; Le Deist F; Lagresle C; Fischer A; Cavazzana-Calvo M; von Kalle C
    Blood; 2005 Apr; 105(7):2699-706. PubMed ID: 15585650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.
    Reinhardt B; Habib O; Shaw KL; Garabedian E; Carbonaro-Sarracino DA; Terrazas D; Fernandez BC; De Oliveira S; Moore TB; Ikeda AK; Engel BC; Podsakoff GM; Hollis RP; Fernandes A; Jackson C; Shupien S; Mishra S; Davila A; Mottahedeh J; Vitomirov A; Meng W; Rosenfeld AM; Roche AM; Hokama P; Reddy S; Everett J; Wang X; Luning Prak ET; Cornetta K; Hershfield MS; Sokolic R; De Ravin SS; Malech HL; Bushman FD; Candotti F; Kohn DB
    Blood; 2021 Oct; 138(15):1304-1316. PubMed ID: 33974038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.
    Aiuti A; Brigida I; Ferrua F; Cappelli B; Chiesa R; Marktel S; Roncarolo MG
    Immunol Res; 2009; 44(1-3):150-9. PubMed ID: 19224139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.
    Dunbar C; Chang L; Mullen C; Ramsey WJ; Carter C; Kohn D; Parkman R; Lenarsky C; Weinberg K; Wara D; Culver KW; Anderson WF; Leitman S; Fleisher T; Klein H; Shearer G; Clerici M; McGarrity G; Bastian J; Hershfield MS
    Hum Gene Ther; 1999 Feb; 10(3):477-88. PubMed ID: 10048399
    [No Abstract]   [Full Text] [Related]  

  • 31. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.
    Laufs S; Nagy KZ; Giordano FA; Hotz-Wagenblatt A; Zeller WJ; Fruehauf S
    Mol Ther; 2004 Nov; 10(5):874-81. PubMed ID: 15509505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene therapy for PIDs: progress, pitfalls and prospects.
    Mukherjee S; Thrasher AJ
    Gene; 2013 Aug; 525(2):174-81. PubMed ID: 23566838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a high incidence region for retroviral vector integration near exon 1 of the LMO2 locus.
    Yamada K; Tsukahara T; Yoshino K; Kojima K; Agawa H; Yamashita Y; Amano Y; Hatta M; Matsuzaki Y; Kurotori N; Wakui K; Fukushima Y; Osada R; Shiozawa T; Sakashita K; Koike K; Kumaki S; Tanaka N; Takeshita T
    Retrovirology; 2009 Sep; 6():79. PubMed ID: 19725963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID.
    Cesana D; Cicalese MP; Calabria A; Merli P; Caruso R; Volpin M; Rudilosso L; Migliavacca M; Barzaghi F; Fossati C; Gazzo F; Pizzi S; Ciolfi A; Bruselles A; Tucci F; Spinozzi G; Pais G; Benedicenti F; Barcella M; Merelli I; Gallina P; Giannelli S; Dionisio F; Scala S; Casiraghi M; Strocchio L; Vinti L; Pacillo L; Draghi E; Cesana M; Riccardo S; Colantuono C; Six E; Cavazzana M; Carlucci F; Schmidt M; Cancrini C; Ciceri F; Vago L; Cacchiarelli D; Gentner B; Naldini L; Tartaglia M; Montini E; Locatelli F; Aiuti A
    Nat Commun; 2024 Apr; 15(1):3662. PubMed ID: 38688902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.
    Deichmann A; Hacein-Bey-Abina S; Schmidt M; Garrigue A; Brugman MH; Hu J; Glimm H; Gyapay G; Prum B; Fraser CC; Fischer N; Schwarzwaelder K; Siegler ML; de Ridder D; Pike-Overzet K; Howe SJ; Thrasher AJ; Wagemaker G; Abel U; Staal FJ; Delabesse E; Villeval JL; Aronow B; Hue C; Prinz C; Wissler M; Klanke C; Weissenbach J; Alexander I; Fischer A; von Kalle C; Cavazzana-Calvo M
    J Clin Invest; 2007 Aug; 117(8):2225-32. PubMed ID: 17671652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
    Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
    Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.
    Cicalese MP; Ferrua F; Castagnaro L; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Roncarolo MG; Aiuti A
    Mol Ther; 2018 Mar; 26(3):917-931. PubMed ID: 29433935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency.
    Kohn DB; Booth C; Shaw KL; Xu-Bayford J; Garabedian E; Trevisan V; Carbonaro-Sarracino DA; Soni K; Terrazas D; Snell K; Ikeda A; Leon-Rico D; Moore TB; Buckland KF; Shah AJ; Gilmour KC; De Oliveira S; Rivat C; Crooks GM; Izotova N; Tse J; Adams S; Shupien S; Ricketts H; Davila A; Uzowuru C; Icreverzi A; Barman P; Campo Fernandez B; Hollis RP; Coronel M; Yu A; Chun KM; Casas CE; Zhang R; Arduini S; Lynn F; Kudari M; Spezzi A; Zahn M; Heimke R; Labik I; Parrott R; Buckley RH; Reeves L; Cornetta K; Sokolic R; Hershfield M; Schmidt M; Candotti F; Malech HL; Thrasher AJ; Gaspar HB
    N Engl J Med; 2021 May; 384(21):2002-2013. PubMed ID: 33974366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retroviral transduction of IL2RG into CD34(+) cells from X-linked severe combined immunodeficiency patients permits human T- and B-cell development in sheep chimeras.
    Tsai EJ; Malech HL; Kirby MR; Hsu AP; Seidel NE; Porada CD; Zanjani ED; Bodine DM; Puck JM
    Blood; 2002 Jul; 100(1):72-9. PubMed ID: 12070011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
    Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
    Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.